SCHEMBL6716864

SCHEMBL6716864

Cc1ccccc1NC(=O)C(N)c1ccsc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.47
SCN1A P35498 1/20 0.47
SCN2A Q99250 1/20 0.47
SCN3A Q9NY46 1/20 0.47
POLB P06746 2/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
MAPT P10636 4/20 0.46
LMNA P02545 3/20 0.46
HPGD P15428 3/20 0.46
GAA P10253 2/20 0.46
ALDH1A1 P00352 2/20 0.46
TP53 P04637 2/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28609335 0.82 RAB9A (0.55) PGRSCN1ASCN2ASCN3APOLB
SCHEMBL6718687 0.82 RAB9A (0.55) PGRSCN1ASCN2ASCN3APOLB
SCHEMBL6718773 0.82 RAB9A (0.55) PGRSCN1ASCN2ASCN3APOLB
SCHEMBL6824939 0.82 POLB (0.46) PGRSCN1ASCN2ASCN3APOLB
Formic Acid SCHEMBL6715482 0.77 CYP1A2 (0.53) PGRSCN1ASCN2ASCN3APOLB
Formic Acid SCHEMBL6717292 0.77 CYP1A2 (0.53) PGRSCN1ASCN2ASCN3APOLB
SCHEMBL6722708 0.77 POLB (0.45) POLBNPC1RAB9AMAPTGAA
SCHEMBL8347137 0.75 CTSS (0.46) PGRSCN1ASCN2ASCN3APOLB
SCHEMBL6715577 0.74 LMNA (0.56) PGRSCN1ASCN2ASCN3APOLB
SCHEMBL8346804 0.74 NPC1 (0.60) PGRSCN1ASCN2ASCN3APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 PGR 2543/4885SCN1A 699/4885SCN2A 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.